BCL2 and breast carcinoma: Additionally, in estrogen receptor α (ERα)-dependent breast cancer, KDM6B forms a complex with ERα and binds to ERα sites in the BCL2 enhancer region, leading to BCL2 overexpression following estrogen treatment (144).